ArticleCureus2025
Development and Validation of a Sensitive Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Method for the Simultaneous Quantification of Thiopurine Nucleotides in Human Red Blood Cells.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Therapeutic drug monitoring (TDM) of thiopurine metabolites in red blood cells (RBCs) is essential to optimizing dosing regimens and minimizing adverse effects. Current analytical methods lack the desirable specificity and sensitivity needed for optimum quantification at therapeutic concentrations on a routine basis. The objectives of the current study were to validate and develop a highly repeatable and specific liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the simultaneous quantification of 6-mercaptopurine (6-MP), 6-thioguanine (6-TG), and 6-methylmercaptopurine (6-MMP) within human red cells. Methods Hydrophilic interaction liquid chromatography (HILIC) was employed for separation using a gradient elution system. Ammonium formate with formic acid in water (A) and acetonitrile (B) was used as the mobile phases. Multiple reaction monitoring (MRM) detection was carried out in positive mode using an electrospray ionization (ESI) source. The method was validated according to International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines and included testing for linearity, accuracy, recovery, precision, and specificity in the 0.5-1000 ng/mL concentration range. Results The developed method showed excellent linearity for the three analytes with a coefficient of determination (R²) of ≥0.9997. Recovery analysis showed acceptable accuracy, with the mean recoveries between 88.74% and 117.37% for all the concentration levels. The method showed high specificity without interference from endogenous matrix components. Precision study showed a relative standard deviation (RSD) of ≤15% for all the analytes. Conclusions The developed LC-MS/MS approach gives a reliable technique for the simultaneous quantification of thiopurine metabolites within erythrocytes. With its reliability and sensitivity, it makes a suitable approach for therapeutic drug monitoring at the clinical level, therefore contributing toward enhanced thiopurine therapy under the banner of personalized medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.